126 related articles for article (PubMed ID: 23676554)
1. Effect of epigallocatechin-3-gallate on graft-versus-host disease.
Choi J; Cooper ML; Ziga ED; Ritchey J; DiPersio JF
Cell Transplant; 2014; 23(9):1163-6. PubMed ID: 23676554
[TBL] [Abstract][Full Text] [Related]
2. The Green Tea Catechin Epigallocatechin Gallate Ameliorates Graft-versus-Host Disease.
Westphal S; McGeary A; Rudloff S; Wilke A; Penack O
PLoS One; 2017; 12(1):e0169630. PubMed ID: 28103249
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of murine graft-versus-host disease by a tea polyphenol.
Kanamune J; Iwanaga Y; Kina T; Noguchi H; Matsumura K; Uemoto S; Hyon SH
Cell Transplant; 2012; 21(5):909-18. PubMed ID: 22330060
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
[TBL] [Abstract][Full Text] [Related]
5. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice.
Ito R; Katano I; Kawai K; Hirata H; Ogura T; Kamisako T; Eto T; Ito M
Transplantation; 2009 Jun; 87(11):1654-8. PubMed ID: 19502956
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate sensitizes IFN-γ-stimulated CD4+ T cells to apoptosis via alternative activation of STAT1.
Wu X; Shao F; Yang Y; Gu L; Zheng W; Wu X; Gu Y; Shu Y; Sun Y; Xu Q
Int Immunopharmacol; 2014 Dec; 23(2):434-41. PubMed ID: 25261409
[TBL] [Abstract][Full Text] [Related]
7. Histological assessment of the sclerotic graft-versus-host response in the humanized RAG2-/-γc-/- mouse model.
Hogenes MC; van Dorp S; van Kuik J; Monteiro FR; ter Hoeve N; van Dijk MR; Martens AC; de Weger RA
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1023-35. PubMed ID: 22579931
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
[TBL] [Abstract][Full Text] [Related]
9. Early myeloid-derived suppressor cells (HLA-DR
Wang K; Lv M; Chang YJ; Zhao XY; Zhao XS; Zhang YY; Sun YQ; Wang ZD; Suo P; Zhou Y; Liu D; Zhai SZ; Hong Y; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
J Hematol Oncol; 2019 Mar; 12(1):31. PubMed ID: 30885244
[TBL] [Abstract][Full Text] [Related]
10. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.
King MA; Covassin L; Brehm MA; Racki W; Pearson T; Leif J; Laning J; Fodor W; Foreman O; Burzenski L; Chase TH; Gott B; Rossini AA; Bortell R; Shultz LD; Greiner DL
Clin Exp Immunol; 2009 Jul; 157(1):104-18. PubMed ID: 19659776
[TBL] [Abstract][Full Text] [Related]
11. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Belfiore L; Ly D; Adhikary SR; Fuller SJ; Varikatt W; Sanderson-Smith ML; Sluyter V; Alexander SI; Sluyter R; Watson D
Clin Exp Immunol; 2017 Oct; 190(1):79-95. PubMed ID: 28665482
[TBL] [Abstract][Full Text] [Related]
12. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
13. S1PR5 regulates NK cell responses in preventing graft-versus-host disease while preserving graft-versus-tumour activity in a murine allogeneic haematopoietic stem cell transplantation model.
Wang F; Zhao S; Gu Z; Zhao X; Yang N; Guan L; Liu T; Wang L; Fang S; Zhu C; Luo L; Li M; Wang L; Gao C
Hematol Oncol; 2020 Feb; 38(1):89-102. PubMed ID: 31465552
[TBL] [Abstract][Full Text] [Related]
14. Modeling Human Graft-Versus-Host Disease in Immunocompromised Mice.
Norelli M; Camisa B; Bondanza A
Methods Mol Biol; 2016; 1393():127-32. PubMed ID: 27033222
[TBL] [Abstract][Full Text] [Related]
15. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation.
Hashimoto D; Chow A; Greter M; Saenger Y; Kwan WH; Leboeuf M; Ginhoux F; Ochando JC; Kunisaki Y; van Rooijen N; Liu C; Teshima T; Heeger PS; Stanley ER; Frenette PS; Merad M
J Exp Med; 2011 May; 208(5):1069-82. PubMed ID: 21536742
[TBL] [Abstract][Full Text] [Related]
16. Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.
Wang J; Li L; Xu M; Rong R; Zhu T
Transplantation; 2013 Nov; 96(9):774-81. PubMed ID: 23900211
[TBL] [Abstract][Full Text] [Related]
17. Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3-positive CD8+ T lymphocytes.
Janikashvili N; Trad M; Gautheron A; Samson M; Lamarthée B; Bonnefoy F; Lemaire-Ewing S; Ciudad M; Rekhviashvili K; Seaphanh F; Gaugler B; Perruche S; Bateman A; Martin L; Audia S; Saas P; Larmonier N; Bonnotte B
J Allergy Clin Immunol; 2015 Jun; 135(6):1614-24.e4. PubMed ID: 25630940
[TBL] [Abstract][Full Text] [Related]
18. Insights into mechanisms of graft-versus-host disease through humanised mouse models.
Elhage A; Sligar C; Cuthbertson P; Watson D; Sluyter R
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 35993192
[TBL] [Abstract][Full Text] [Related]
19. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
Leng C; Gries M; Ziegler J; Lokshin A; Mascagni P; Lentzsch S; Mapara MY
Exp Hematol; 2006 Jun; 34(6):776-87. PubMed ID: 16728283
[TBL] [Abstract][Full Text] [Related]
20. Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
Mochizuki K; Meng L; Mochizuki I; Tong Q; He S; Liu Y; Purushe J; Fung H; Zaidi MR; Zhang Y; Reshef R; Blazar BR; Yagita H; Mineishi S; Zhang Y
Blood; 2016 Jun; 127(25):3270-80. PubMed ID: 27143255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
